Although this difference did not reach statistical significance, mesalazine was associated with significant improvements in physical condition and quality-of-life scores ( p = 0.02) and with a 20% reduction in concomitant gastrointestinal drug use ( 9 ).
← all excerpts
Risk-stratified pharmacologic strategies for secondary prevention after acute diverticulitis: an exploratory narrative review and research framework.
1
0.0200
0.0200